Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 04 January 2013 | By Alexander Gaffney, RAC,
The European Medicines Agency (EMA) has released a newly-revised draft guideline regarding the development of pharmaceutical products intended for use in children, taking into account comments received on a draft version released in 2011.
The changes made to the initial draft guideline, Guideline on pharmaceutical development of medicines for paediatric use, were reportedly significant enough for EMA to partially restart the comment period on the guideline, which is now open through 31 March 2013.
The guideline aims to clarify some of the requirements surrounding the EU "Pediatric Regulation," which is intended to guide the development of pediatric medicines. The overarching objective of the Pediatric Regulation, observes EMA, is to make sure medicinal products are effective through highly targeted clinical trials, while at the same time ensuring that trial subjects are not subject to a product with a negative risk-benefit assessment.
Unlike the original consultation period, EMA said it will only consider three sections of the guideline for comment: Section 6.2.1 (Handling of oral solid preparations to facilitate administration), Section 10 (Mixing with food) and a section on patient acceptability.
EMA explained that these sections have experienced changes as the result of comments. Section 6.2.1., for example, is significantly revised and expanded, with considerable additional detail given to the use of tablets, capsules, chewable preparations and alternate dosing strategies such as crushing, liquid dispersion and the use of food. If food or drink items are used to facilitate treatment, EMA noted that sponsors will need to ensure that a variety of factors are controlled, including the temperature of the food products, the portion size, the time of consumption after which the products are combined, and any potential effects of the food product on the medicinal product being studied.
Finally, EMA has worked these concepts into a revised section on "patient acceptability," which now links up the attributes of a treatment regimen-palatability, swallowability, complexity of handling, required dose and dose frequency, route of administration, etc.-with whether or not a patient should be considered for a clinical trial. A mismatch between a patient and a product is more likely to cause a patient to drop out of the trial or not properly adhere to a treatment regimen, EMA noted.
The section also delves deeper into the issue of palatability, which EMA now notes is something of a requirement rather than an aspiration. "Unless otherwise justified, the palatability of a paediatric medicine should be satisfactory on its own merit (i.e. without mixing with food or drinks)," it wrote. Product sponsors should therefore take into account the excipients, flavoring agents, particle size, coating, or complexing agents used in an oral solid-dose medication. Similar measures should be taken for oral liquid-dose drugs as well, EMA explained.
Comments on the draft guidance should be sent to qwp@ema.europa.eu by 31 March 2013.
Tags: Paediatric, Pediatric
Regulatory Focus newsletters
All the biggest regulatory news and happenings.